CAI
Caris Life Sciences Inc
$28.20
▼ 0.5%Updated Oct 2, 3:37 PM ET
CAI at a glance — five pillars scored 0–100 from real filed financials.
Overall: Unrated · 0/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Market Cap
$0.00
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
4.0%
Interest Coverage
—
Current Ratio
5.53x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
0/100
Caris Life Sciences Inc (CAI) is a small-cap company in the Biotechnology industry, part of the Health Care sector of the S&P 500.
In its latest reported year it generated about $812.03M in revenue and posted a net loss of $68.09M.
Our model rates CAI Unrated (0/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
2Y CAGR
62.9%
Revenue moved from $306.13M in 2023 to $812.03M in 2025, a 62.9% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.
Gross Margin
—
Operating Margin
5.6%
Net Margin
-8.4%
ROE
—
Total Debt
$392.69M
Net Debt
-$427.21M
Net cash position
Net Debt / EBITDA
-9.47x
Debt / Equity
—
Leverage: debt-to-equity is n/a, with a current ratio of 5.5x. Detailed balance-sheet leverage is limited for this name. It carries roughly $392.69M of total debt against $819.90M of cash.
Operating CF
$83.16M
Free Cash Flow
$66.89M
FCF Margin
8.2%
In the latest year Caris Life Sciences Inc produced about $83.16M of operating cash flow and $66.89M of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
—
P/S
—
P/B
—
EV / EBITDA
—
CAI trades at n/a trailing earnings. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$4.06
Current price
$28.20
Starting FCF (latest 10-K)
$66.89M
Growth, years 1–5
4.0%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where CAI sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How CAI stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), CAI ranks #131 of 324 by our overall rating.
P/E vs sector
—
median 26x
ROE vs sector
—
median 14.1%
Growth vs sector
—
median 7.6%
Sector rank
#131
of 324 by rating
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $28.20 today · expected CAGR -44% – -38%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $877.00M | $947.16M | $1.02B | $1.10B | $1.19B |
| Net income | $26.31M | $28.41M | $30.69M | $33.14M | $35.79M |
| EPS | $0.09 | $0.10 | $0.11 | $0.12 | $0.13 |
| Share price (low) | $1.12 | $1.21 | $1.30 | $1.41 | $1.52 |
| Share price (high) | $1.86 | $2.01 | $2.17 | $2.35 | $2.53 |
| CAGR (low–high) | -96% / -93% | -79% / -73% | -64% / -57% | -53% / -46% | -44% / -38% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for CAI:
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against CAI:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Caris Life Sciences Inc is a small-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Unrated (0/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Latest SEC Filings
CAI's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
CAI — frequently asked questions
Is CAI a good stock to buy?
We don't give buy or sell advice. Review Caris Life Sciences Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does CAI's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Caris Life Sciences Inc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for CAI calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this CAI analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell CAI. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.